0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Menopause

Conditions

Menopause, Postmenopausal Bleeding

Trial Timeline

May 1, 2010 โ†’ Jun 1, 2013

About 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) is a pre-clinical stage product being developed by Novo Nordisk for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT01076621. Target conditions include Menopause, Postmenopausal Bleeding.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01076621Pre-clinicalCompleted